Cara Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
TVRD$1.410.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, | |||||||||
| · 2023 · 2022 · 2021 | |||||||||
| Operating activities · · · · · | |||||||||
| Net loss | | $(118,513) | | $(85,474) | | $(88,441) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | |||||
| Stock-based compensation expense | | 13,730 | | 17,734 | | 20,785 | |||
| Non-cash interest expense on liability related to sales of future royalties and milestones, net of issuance costs accretion | | | 604 | | | — | | | — |
| Depreciation and amortization | | 259 | | 248 | | 248 | |||
| Noncash lease expense | | 2,075 | | 1,422 | | 1,306 | |||
| (Accretion)/amortization of available-for-sale marketable securities, net | | | (400) | | | 264 | | | 861 |
| Realized gain on sale of available-for-sale marketable securities | | — | | — | | (39) | |||
| Realized gain on sale of property and equipment | | — | | — | | (70) | |||
| Changes in operating assets and liabilities: | | | | | | ||||
| Accounts receivable, net - related party | | | 495 | | | (3,260) | | | — |
| Inventory, net | | | (438) | | | 201 | | | (2,584) |
| Income tax receivable | | | — | | | — | | | 810 |
| Other receivables | | (59) | | (41) | | 102 | |||
| Prepaid expenses | | 8,113 | | (13,748) | | 9,557 | |||
| Accounts payable and accrued expenses | | 3,275 | | 5,679 | | (1,020) | |||
| Operating lease liabilities | | | (1,918) | | | (1,755) | | | (1,602) |
| Reimbursement of lease incentive | | | 807 | | | — | | | — |
| Other | | | (108) | | | — | | | — |
| Net cash used in operating activities | | (92,078) | | (78,730) | | (60,087) | |||
| Investing activities | | | | ||||||
| Proceeds from maturities of available-for-sale marketable securities | | 155,441 | | 220,435 | | 173,484 | |||
| Proceeds from redemptions of available-for-sale marketable securities, at par | | | 4,000 | | | 4,000 | | | 20,500 |
| Proceeds from sale of available-for-sale marketable securities | | — | | — | | 10,029 | |||
| Purchases of available-for-sale marketable securities | | (113,605) | | (95,685) | | (208,795) | |||
| Purchases of property and equipment | | | (2,375) | | | (43) | | | (39) |
| Proceeds from sale of property and equipment | | — | | — | | 70 | |||
| Net cash provided by (used in) investing activities | | 43,461 | | 128,707 | | (4,751) | |||
| Financing activities | | | | | |||||
| Proceeds from royalty purchase and sale agreement, net of $1.0 million of issuance costs | | | 36,474 | | | — | | | — |
| Net proceeds from sales of common stock under open market sales agreement | | | 1,117 | | | — | | | — |
| Proceeds from the exercise of stock options | | 560 | | 311 | | 1,639 | |||
| Proceeds from the sale of common stock under license agreement with Vifor International | | | — | | | — | | | 44,969 |
| Net cash provided by financing activities | | 38,151 | | 311 | | 46,608 | |||
| Net (decrease) increase in cash, cash equivalents and restricted cash | | (10,466) | | 50,288 | | (18,230) | |||
| Cash, cash equivalents and restricted cash at beginning of period | | 64,149 | | 13,861 | | 32,091 | |||
| Cash, cash equivalents and restricted cash at end of period | | $53,683 | | $64,149 | | $13,861 | |||
| Noncash investing and financing activities | | | | | | | | ||
| Accrual for leasehold improvements | | $778 | | $— | | $— | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.